Table 5.
Risk of venous thrombosis by percentiles of apolipoproteins B and A1 levels adjusted for hemostatic factors and c-reactive protein
| Pooled control analyses | Partner control analyses | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | (95% CI)a | OR | (95% CI)ab | OR | (95% CI)abc | OR | (95% CI)a | OR | (95% CI)ab | OR | OR (95% CI)abc | |
| Apo B (g L−1) | ||||||||||||
| <10th (<0.68) | 1.38 | (1.14–1.67) | 1.58 | (1.28–1.93) | 1.86 | (1.49–2.31) | 1.29 | (0.97–1.71) | 1.44 | (1.06–2.00) | 1.59 | (1.12–2.25) |
| 10th–25th (0.68-0.80) | 1.13 | (0.95-1.33) | 1.22 | (1.02–1.45) | 1.36 | (1.13–1.64) | 1.04 | (0.81–1.34) | 1.22 | (0.93–1.59) | 1.29 | (0.97–1.72) |
| 25th–75th (0.80–1.15) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| 75th– 90th (1.15–1.33) | 0.98 | (0.83–1.17) | 0.88 | (0.74–1.06) | 0.81 | (0.67–0.98) | 0.98 | (0.76–1.28) | 1.09 | (0.82–1.45) | 1.01 | (0.74–1.37) |
| >90th (>1.33) | 0.80 | (0.65–0.99) | 0.72 | (0.58–0.90) | 0.63 | (0.49–0.80) | 0.84 | (0.60–1.17) | 0.88 | (0.62–1.26) | 0.88 | (0.59-1.31) |
| Apo A 1 (g L−1) | ||||||||||||
| <10th (< 1.09) | 1.42 | (1.18–1.72) | 1.29 | (1.05–1.57) | 1.20 | (0.98–1.48) | 1.24 | (0.93–1.65) | 1.17 | (0.85–1.59) | 1.09 | (0.78–1.52) |
| 10th–25th (1.09–1.22) | 1.08 | (0.91–1.28) | 1.01 | (0.84-1.20) | 0.98 | (0.82–1.18) | 1.03 | (0.80–1.33) | 0.96 | (0.73–1.27) | 0.97 | (0.73–1.30) |
| 25th– 75th (1.22-1.59) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) | 1 | (reference) |
| 75th– 90th (1.59–1.81) | 0.88 | (0.73–1.04) | 0.99 | (0.83–1.20) | 1.02 | (0.85–1.24 | 0.83 | (0.63–1.08) | 0.88 | (0.66–1.17) | 0.91 | (0.67–1.22) |
| >90th (>1.81) | 0.71 | (0.56–0.88) | 0.86 | (0.68–1.09) | 0.84 | (0.66–1.08) | 0.65 | (0.45–0.93) | 0.65 | (0.44–0.96) | 0.67 | (0.46–1.00) |
Data were missing for some participants in some subgroups
OR odds ratio, CI confidence interval, Apo B apolipoprotein B, apo A1 apolipoprotein A1
aAdjusted for age, sex and partnership (where applicable)
bAdjusted for body mass index, estrogen use at blood sampling, statin use, and self-reported diabetes
cAdjusted for potential mediators for apolipoprotein B (protein C, protein S, antithrombin, tissue factor pathway inhibitor, fibrinogen, factors II, VII, IX, X, and XI, clot lysis time, and c-reactive protein) or for apolipoprotein A1 (protein C, fibrinogen, factors II, VII, IX, X, and XI, and c-reactive protein)
ORa and ORab were slightly different from those depicted in Table 2 because vitamin K antagonist users at the time of blood sampling (n = 271 patients and n = 27 controls) were excluded from the mediation analyses
ORabc (further adjustment for potential mediators) is in bold